Long-term follow-up of prolactinomas: Should dopamine agonist treatment be life-long?

Frontiers of Hormone Research

Volumn 35, Issue , 2006, Pages 88-101

  Guitelman, Mirtha ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL DURAND   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN;

ADENOMA; ADOLESCENT; ADULT; ALGORITHM; BLOOD; COMPARATIVE STUDY; CONFERENCE PAPER; FEMALE; FOLLOW UP; HUMAN; HYPOPHYSIS TUMOR; LONG TERM CARE; MALE; MIDDLE AGED; PROLACTINOMA; RETROSPECTIVE STUDY; TIME; TREATMENT WITHDRAWAL; TUMOR RECURRENCE;

ADENOMA; ADOLESCENT; ADULT; ALGORITHMS; DOPAMINE AGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RETROSPECTIVE STUDIES; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 33745782369     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000094312     Document Type: Conference Paper

References (58)

1. Besser GM, Parke L, Edwards CRW, Forsyth LA, Mc Neilly AS: Galactorrhea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine. J Clin Endocrinol Metabol 1984;58:268-273.
2. Spark RF, Baker R, Bienfang DC, Bergland R: Bromocriptrne reduces pituitary tumor size and hypersecretion: requiem for pituitary surgery? J Am Med Assoc 1982;247:311-316.
3. Molitch ME: Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 1999;28:143-169
4. Faglia G: Should dopamine agonist treatment for prolactinomas be life-long? Clin Endocrinol (Oxf) 1991;34:173-174.
5. Zarate A, Canales ES, Cano C, Pilonieta CJ: Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol (Copenh) 1983;104:139-142.
6. Johnston DG, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook DB: Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas: studies with high-definition computerized tomography. Lancet 1984;ii:187-192.
7. Ho KY, Smythe GA, Compton PJ, Lazarus SL: Long-term bromocriptine therapy may restore the inhibition control of prolactin release in some patients with pathological hyperprolactinemia. Aust NZ J Med 1985;15:213-219.
8. Moriondo P, Travaglini P, Nissim M, Conti A, Faglia G: Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 1985;60:764-772.
9. Wang C, Lam KS, Ma JT, Chan T, Liu MY, Yeung RT: Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol (Oxf) 1987;27:363-371.
10. Rasmussen C, Bergh T, Wide L: Prolactin secretion and menstrual function after long-term bromocriptine treatment. Fertil Steril 1987;48:550-554.
11. van't Verlaat JW, Croughs RJ: Withdrawal of bromocriptine after long-term therapy for macroprolactinomas, effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf) 1991;34:175-178.
12. Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, Dálberton A, Crosignani P: Cabergoline in the long-term therapy of hyperprolactinemia disorders. Acta Endocrinol (Copenh) 1992;126:489-494.
13. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G: Use of Cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 1997;20:537-546.
14. Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F: Cabergoline: a first choice treatment in patients with previously untreated prolactin-secreting pituitary adenomas. J Endocrinol Invest 1999;22:354-359.
15. Karunakaran S, Page RC, Wass JA: The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 2001;54:295-300.
16. Passos VQ, Souza J, Musolino N, Bronstein MD: Long term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 2002;87:3578-3582.
17. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G: Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003;349:2023-2033.
18. Biswas M, Smith J, Jadon D, Mc Ewan P, Rees DA, Evans LM, Scanion MF, Davies JS: Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 2005;63:26-31.
19. Mehmet S, Powrie JK: A survey of dopamine agonist withdrawal policy in UK endocrinologist treating patients with prolactinomas. Clin Endocrinol (Oxf) 2003;58:111-113.
20. Maurer RA: Dopaminergic inhibition of prolactin synthesis and prolactin messenger RNA accumulation in cultured pituitary cells. J Biol Chem 1980;255:8092-8097.
21. Bassetti M, Spada A, Pezzo G, Giannattasio G: Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. J Clin Endocrinol Metab 1984;58:268-273.
22. Tindall GT, Kovacs K, Horvath E, Thorner MO: Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 1982;55:1178-1183.
23. Gen M, Uozumi T, Ohta M, Ito A, Kajiwara H, Mori S: Necrotic changes in prolactinomas after long-term administration of bromocriptine. J Clin Endocrinol Metab 1984;59:463-470.
24. Stefaneanu L, Kovacs K, Scheithauer BW, Kontogeorgos G, Riehle DL, Sebo TJ, Murray D, Vidal S, Tran A, Buchfelder M, Fahlbusch R: Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocr Pathol 2000;11:341-352.
25. Gruszka A, Pawlikowski M, Kunert-Radek J: Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: antiproliferative and pro-apoptotic effects. Neuroendocrinol Lett 2001;22:343-348.
26. Lubina D, Olchovsky M, Berezin Z, Ram M, Hadani M, Shimon I: Management of pituitary apoplexy: clinical experience with 40 patients. Acta Neurochir 2005;147:151-157.
27. Knoepfelmacher M, Gomes MC, Melo ME, Mendonça BB: Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma Pituitary 2005;7:83-87.
28. Thorner MO, Perryman RL, Rogol AD, Conway BP, Macleod RM, Login IS, Morris JL: Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 1981;53:480-483.
29. Orrego JJ, Chandler WF, Barkan AL: Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine. Pituitary 2000;3:189-192.
30. Koppelman MC, Jaffe MJ, Rieth KG, Caruso RC, Louriaux DL: Hyperprolactinemia, amenorrhea, and galactorrhea: a retrospective assessment of twenty-five cases. Ann Intern Med 1984;100:115-121.
31. March CM, Kletzky OA, Davajan V, Teal J, Weiss M, Apuzzo ML, Marrs RP, Mishell DR Jr: Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 1981;139:835-844.
32. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A: The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989;68:412-418.
33. Sisam DA, Sheehan JP, Sheeler LR: The natural history of untreated microprolactinomas. Fertil Steril 1987;48:67-71.
34. Rjosk HK, Fahlbusch R, von Werder K: Spontaneous development of hyperprolactinemia. Acta Endocrinol (Copenh) 1982;100:333-336.
35. Martin TL, Kim M, Malarkey WB: The natural history of idiopathic hyperprolactinemia. J Clin Endocrinol Metab 1985;60:855-858.
36. Weiss MH, Teal J, Gott P, Wycoff R, Yadley R, Apuzzo ML, Giannotta SL, Kletzky O, March C: Natural history of microprolactinomas: six-year follow-up. Neurosurgery 1983;12:180-183.
37. Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J: Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 1996;45:299-303.
38. Villarreal JZ: Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. Am J Med 1988;85:217-220.
39. Molitch ME: Pregnancy and the hyperprolactinemic woman. N Engl JMed 1985;312:1365-1370.
40. Molitch ME: Management of prolactinomas during pregnancy. J Reprod Med 1999;44:1121-1126.
41. Badawy SZ, Marziale JC, Rosenbaum AE, Chang JK, Joy SE: The long-term effects of pregnancy and bromocriptine treatment on prolactinomas - the value of radiologie studies. Early Pregnancy 1997;3:306-311.
42. Ahmed M, al-Dossary E, Woodhouse NJ: Macroprolactinomas with supraselar extension: effect of bromocriptine withdrawal during one or more pregnancies. Fertil Steril 1992;58:492-497.
43. Crosignani PG, Mattei AM, Severini V, Cavioni V, Maggioni P, Testa G: Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obstet Gynecol Reprod Biol 1992;44:175-180.
44. Bronstein MD, Salgado LR, Musolino NR: Medical management of pituitary adenomas: the special case of management of the pregnant woman. Pituitary 2002;5:99-107.
45. Jaita AG, Candolfi M, Zaldivar V, Zárate S, Ferrari L, Pisera D, Castro MG, Seilicovich A: Estrogens up-regulate the Fas/FasL apoptotic pathway in lactotropes. Endocrinology 2005;146:4737-4744.
46. Selman WR, Laws ER Jr, Scheithauer BW, Carpenter SM: The occurrence of dural invasion in pituitary adenomas. Neurosurgery 1986;64:402-407.
47. Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER: The long-term significance of microscopic durai invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurgery 2002;96:195-208.
48. Juliani G, Avataneo T, Potenzoni F, Sorrentino T: CT and MRI compared in the study of hypophysis. Radiol Med (Torino) 1989;77:51-64.
49. Guy RL, Benn JJ, Ayers AB, Bingham JB, Lowy C, Cox TC, Sonksen PH: A comparison of CT and MRI in the assessment of the pituitary and parasellar region. Clin Radiol 1991;43:156-161.
50. Webb SM, Ruscalleda J, Schwarzstein D, Calaf-Alsina J, Rovira A, Matos G, Puig-Domingo M, de Leiva A: Computerized tomography versus magnetic resonance imaging: a comparative study in hypothalamic-pituitary and parasellar pathology. Clin Endocrinol (Oxf) 1992;36:459-465.
51. Teramoto A, Hirakawa K, Sanno N, Osamura Y: Incidental pituitary lesions in 1,000 unselected autopsy specimens. Radiology 1994;193:161-164.
52. Reincke M, Allolio B, Saeger W, Menzel J, Winkelmann W: The 'incidentaloma' of the pituitary gland. Is neurosurgery required? JAMA 1990;263:2772-2776.
53. Aron DC, Howlett TA: Pituitary incidentalomas. Endocrinol Metab Clin North Am 2000;29:205-221.
54. Stein AL, Levenick MN, Kletzky OA: Computed tomography versus magnetic resonance imaging for the evaluation of suspected pituitary adenomas. Obstet Gynecol 1989;73:996-999.
55. Chanson P, Daujat F, Young J, Bellucci A, Kujas M, Doyon D, Schaison G: Normal pituitary hypertrophy as a frequent cause of pituitary incidentaloma: a follow-up study. J Clin Endocrinol Metabol 2001;86:3009-3015.
56. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G: Macroprolactinoma shrinkage during cabergoline treatment is greater in naïve patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metabol 2000;85:2247-2252.
57. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994;331:904-909.
58. 8 Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A: Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518-2522.